[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vishwajit Nimgaonkar, MD PhD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100430646","phase-1-acetazolamide-for-treatment-resistant-schizophrenia-100430646",false,"NCT04887792","Acetazolamide for Treatment Resistant Schizophrenia","A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia","APTS","Inclusion Criteria:\n\n* Written informed consent.\n* Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).\n* PANSS total score \\> 60 and Score \\> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.\n* Stable dose of antipsychotic drug (APD) for \\> 1 month, continued throughout the study.\n* Not participating in another randomized controlled clinical trial (RCT).\n\nExclusion Criteria:\n\n* Substance abuse in the past month\u002Fdependence past 6 months with the exception of methadone prescribed for opiate withdrawal.\n* History or current medical\u002Fneurological illnesses that may lead to unstable course, e.g., epilepsy.\n* Pregnancy.\n* Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease\u002Fadrenal failure; chronic closed angle-closure glaucoma.\n* Current or prior treatment with ACZ or history of hypersensitivity to ACZ.\n* Intellectual disability as defined in DSM 5.","ALL","18 Years","55 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.",[29,30],"Schizophrenia","Schizo Affective Disorder",[29,30,32],"acetazolamide","RECRUITING","2026-04-06",{"date":36,"type":37},"2026-04-07","ACTUAL",{"date":39,"type":37},"2022-02-01",{"date":41,"type":22},"2026-12-30",{"name":43,"class":44},"Vishwajit Nimgaonkar, MD PhD","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100346694","phase-1-cromoglicate-adjunctive-therapy-for-outpatients-with-schizophrenia-100346694","NCT03794076","Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia","Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia","CATOS","Inclusion Criteria:\n\n* Written informed consent.\n* Both genders, ages 18-60 years\n* Schizophrenia \u002F schizoaffective disorder (DSM V).\n* Treated with the same APD for at least 60 days; Stable dose of APD for \\> 1 month, continued throughout the study.\n* PANSS total score of 60 and Score 4 or more on one or more items of the 'positive' syndrome items (P1-P7)\n* Preference for patients with duration of psychosis less than 7 years.\n\nExclusion Criteria:\n\n* No illicit substance use in last 30 days\u002Fno dependence in 6 months with the exception of methadone treatment for opioid withdrawal.\n* History or current medical \u002Fneurological illnesses that may lead to an unstable course with the exception of epilepsy which is well-controlled on an antiepileptic medication for at least 6 months.\n* Pregnancy.\n* History of immune disorders, HIV infection, or receiving immune-suppressants or immuno-modulators, e.g., steroids.\n* Current or prior treatment with CGY or History of hypersensitivity to CGY.\n* Intellectual disability as defined in DSM V.","65 Years",{"count":55,"type":22},160,[25,26],"This is a double blind adjunctive randomized controlled trial for schizophrenia using cromoglicate.",[29,30],[60,61,62],"schizophrenia","schizoaffective disorder","cromoglicate","2026-03-16",{"date":65,"type":37},"2026-03-19",{"date":67,"type":37},"2019-04-01",{"date":69,"type":22},"2028-06",{"name":43,"class":44},1,""]